HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022
Journal of Antimicrobial Chemotherapy · 01.08.2025 · 80 (8) · 2126-2134
DOI: 10.1093/jac/dkaf180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 09.06.2025. Verfasst von Christine Watera und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Virololgy, Uganda Virus Research Institute (UVRI), Entebbe, Uganda. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, Oxazines, HIV-1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Centers for Disease Control and Prevention (U.S. CDC).
Abstract (Originalsprache)
Background and objectives Uganda adopted dolutegravir as its preferred HIV treatment regimen in the national guidelines for treatment of HIV and AIDS in 2018. We conducted a survey to estimate dolutegravir resistance 4 years post-dolutegravir introduction in routine clinical settings. This was a cross-sectional survey to estimate the prevalence of HIV drug resistance (HIVDR) to dolutegravir among children and adults with viral non-suppression (VNS; ≥1000 copies/mL) receiving dolutegravir-based antiretroviral therapy for at least 9 months.
Methods
We used remnant specimens from routine viral load monitoring stored at Central Public Health Laboratories during February–April 2022. Genotyping of the protease, reverse transcriptase and integrase regions of the HIV-1 pol gene was done using Thermo Fisher® kits and analysed using the Stanford HIVDR database. Weighted prevalences of HIVDR with 95% confidence intervals (CI) were estimated for adults (≥15 years) and children (0–14 years).
Results
We randomly selected 857 specimens including 457 from adults and 400 from children for HIVDR testing from 3578 eligible specimens collected during February–April 2022. Five hundred and eleven (59.6%) were successfully genotyped in the integrase region. Intermediate- to high-level dolutegravir HIVDR prevalence was 3.9% (CI: 0.7, 7.1) for adults and 6.6% (CI: 3.5, 9.6) for children.
Conclusion
HIVDR to dolutegravir was uncommon but present among both children and adults with VNS after 9 months or more of exposure to dolutegravir. Additional longitudinal outcomes data are needed to determine if adherence counselling for patients with VNS on dolutegravir regimens might improve outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General Virololgy, Uganda Virus Research Institute (UVRI), Entebbe, Uganda.
- Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Atlanta, USA.
- Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Kampala, Uganda.
- Sequencing Platform, Medical Research Council (MRC)/UVRI & London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
- Central Public Health Laboratories, Ministry of Health, Kampala, Uganda.
- AIDS Control Program, Ministry of Health, Kampala, Uganda.
ORCID-Profile: Deogratius Ssemwanga, Sherri Pals, Elliot Raizes
Förderung
- U.S. Centers for Disease Control and Prevention (U.S. CDC)
Zitieren
APA
Watera, C., Da Silva, J. F., Namayanja, G., Asio, J. N., Ssemwanga, D., Pals, S., Nabukenya, M., Raizes, E., Nanyonjo, M., Elur, B., Nazziwa, E., Sanyu, G., Ayitewala, A., Ssali, M., Katureebe, C., Balidawa, H., Zheng, D. P., Zeh, C., Hackett, S., …, & Kaleebu, P. (2025). HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022. Journal of Antimicrobial Chemotherapy, 80(8), 2126-2134. https://doi.org/10.1093/jac/dkaf180
Vancouver
Watera C, Da Silva JF, Namayanja G, Asio JN, Ssemwanga D, Pals S, et al. HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022. Journal of Antimicrobial Chemotherapy. 2025;80(8):2126-2134. doi:10.1093/jac/dkaf180
BibTeX
@article{Watera2025,
author = {Watera, Christine and Da Silva, Juliana de Fatima and Namayanja, Grace and Asio, Juliet Nkugwa and Ssemwanga, Deogratius and Pals, Sherri and Nabukenya, Miriam and Raizes, Elliot and Nanyonjo, Maria and Elur, Bill and Nazziwa, Esther and Sanyu, Grace and Ayitewala, Alisen and Ssali, Mina and Katureebe, Cordelia and Balidawa, Hudson and Zheng, Du-Ping and Zeh, Clement and Hackett, Stephanie and Mwangi, Christina and Naluguza, Mary and Ntale, Jonathan and Katongole Mbidde, Edward and Kaleebu, Pontiano},
title = {HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {8},
pages = {2126--2134},
doi = {10.1093/jac/dkaf180}
}
EUVIMED